Leading in the News.
Substitution Of Pegylated Liposomal Doxorubicin For Gemcitabine In Standard Platinum-Based Regimen May Improve Survival In Patients With Recurrent Ovarian Cancer. (4/21, Harrison) reports researchers found in a phase 3 trial that “replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer.” Researchers found that “in a cohort […]